Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Erlotinib in Gemcitabine-Refractory Metastatic Pancreatic Cancer
NCT00365144Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in pancreatic cancer (PC), sponsored by University of California, San Francisco. Primary endpoints: Overall Survival Rate at 6 Months and Safety and Toxicity at 21 weeks. Started Feb 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00365144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365144.